Glenn Rockman

Prior to his role at Adjuvant and his efforts to finance global health R&D programs on behalf of the Bill & Melinda Gates Foundation, Glenn was an Executive Director in J.P. Morgan’s Social Finance unit, where he helped the firm’s non-profit clients maximize the financial resources available to advance their missions. He served in similar capacities at J.P. Morgan for more than a decade before leaving to focus exclusively on financing public health innovations.

At Adjuvant, Glenn oversees the firm’s investments in VitriVax (board member), Univercells (board member), Themis (acquired by Merck in 2020), X-Vax (board observer), InDevR (board member), and Codagenix (board member). He is also actively engaged with the Research Investment for Global Health Technology Fund (RIGHT Fund) as a board member and a champion of leveraging the strengths of South Korea’s life sciences industry to bring new public health innovations to market.

True to his conviction in the power of capital markets and impact investing to drive improvements in livelihoods around the world, he recently added a board seat at WaterEquity to his commitments.

Glenn earned an AB in public policy from the Princeton School of Public and International Affairs.